ArticleBMC medicine2016
The importance of collecting structured clinical information on multiple sclerosis.
Article in BMC medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Trial
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.BMC neurology · 2016Trial
- Delivering high-quality multiple sclerosis care in Germany: challenges and regional models.Neurological research and practice · 2026Review
- Real-World Data for Safety Studies: Challenges and Opportunities From the Italian Multiple Sclerosis and Related Disorders Register.Pharmacoepidemiology and drug safety · 2026Article
- Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.Journal of neurology · 2026Observational
- Finnish Registry-Based Protocol for Screening and Management of Fatigue and Cognitive Problems in Multiple Sclerosis: Observational Study.JMIR human factors · 2025Observational
- Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.Journal of neurology · 2025Article
- Medical Digital Twin: A Review on Technical Principles and Clinical Applications.Journal of clinical medicine · 2025Review
- From implementation to discontinuation: multi-year experience with the multiple sclerosis performance test as a digital monitoring tool.Frontiers in digital health · 2025Article
- MS brain health quality standards: a survey on the reality in clinical practice in Germany.Neurological research and practice · 2024Article
- MyMS: An Interface for Patient-Reported Outcomes for Finnish Individuals With Multiple Sclerosis.International journal of MS care · 2024Article
- Protecting the elderly from influenza in the context of immune system senescence. Elderly aged 65 and over are vulnerable to influenza and its associated complications.: Position paper by the Romanian Society of Gerontology and Geriatrics.Journal of medicine and life · 2024Article
- Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study.Clinical epidemiology · 2024Article
- Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS).Journal of clinical medicine · 2023Article
- Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.Neurological research and practice · 2022Article
- Recommendations for the use of propensity score methods in multiple sclerosis research.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Review
- Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.Journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized controlled trials (RCTs) are the 'gold standard' in the generation of drug efficacy and safety evidence. However, enrolment criteria, timelines and atypical comparators of RCTs limit their relevance to standard clinical practice. DISCUSSION: Real-world data (RWD) provide longitudinal information on the comparative effectiveness and tolerability of drugs, as well as their impact on resource use, medical costs, and pharmacoeconomic and patient-reported outcomes. This is particularly important in multiple sclerosis (MS), where economic treatment benefits of long-term disability reduction are a cornerstone of payer drug approvals - these are typically not examined in the RCT itself but modelled using real-world datasets. Importantly, surrogate markers used in RCTs to predict the prevention of long-term disability progression can only truly be assessed through RWD methodologies. We discuss the differences between RCTs and RWD studies, describe how RWD complements the evidence base from RCTs in MS, summarize the different methods of RWD collection, and explain the importance of structuring data analysis to avoid bias. Guidance on performing and identifying high-quality real-world evidence studies is also provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.